Published 13 hours ago
Submitted by biogene
Healthy Climate, Healthy Lives™ is Biogen’s groundbreaking initiative to eliminate fossil fuels from our operations and address climate, health and equity – issues that have never been more urgent.
In year two, we agreed to a Scientific Advisory Council to guide our program, analyzed the environmental impact of another three products, and strengthened our plan to reduce scope 3 emissions, setting a science-based target to achieve net zero emissions by 2045. Below are progress highlights across the three pillars of Healthy Climate, Healthy Lives, all designed to foster a healthier, more sustainable and equitable world.
Fossil Fuel Free Operations
- Zero fossil fuel emissions from Biogen operations
- 100% Renewable Electricity
- All products achieve and sustain more than 90% of green chemistry targets
- Eliminate, minimize, or closed-loop recycle all fossil fuel derived plastics
- zero emissions from our fleet
- Reduce scope 3 emissions by 90% by 2045 from 2019
- 6% reduction direct emissions (2019 – 2021)
- sustained 100% Renewable Electricity
- 41 Biogen labs enrolled to achieve “My Green Labs” certification
- Completed lifecycle analysis for three biosimilars
- Grow our electric vehicle program to 12 countries
- 7% reduction of scope 3 emissions (2019 – 2021).
- 18% of Biogen’s top 80% of suppliers, by spend, have SBTi-approved targets
Addressing Product Lifecycles
In 2022, we completed a life cycle assessment (LCA) of three biosimilars products – Benepali™, Flixabi™ and Imraldi™ – across multiple configurations in France, Germany, Sweden and the UK The LCA provided new insights on climate impacts from material selection to manufacturing and distribution to end-of-life. We found that just a few processes are the biggest contributors to our products’ carbon and air pollution footprints. Now, the team is working on an action plan to address these impacts.
Creating a Culture of Sustainability in Science
Biogen piloted the My Green Labs program in 2021, with 14 labs achieving third-party certification for sustainability practices, including water, energy and plastics. Now, Tooba Gilani, a Senior Associate in EHS, has championed the program’s expansion to 41 labs globally, saying, “the My Green Labs program encourages people who might not have been thinking about sustainability to start acting on it.”
Biogen’s Product and Technology Development team have also been hard at work, developing and implementing their principles for sustainable development. These principles will help to promote environmentally conscious decisions within our operations.
- Engage employees
- Help employees to go fossil fuel free in their homes
- +15% of Biogen employees involved in Healthy Climate Healthy Lives programs
- More than 800 employees participating in Biogen’s “green benefits”
Inspiring and Connecting Employees to Our Goals
Melanie Horkan and Caitlyn Plunkett joined our IMPACT, Biogen’s employee resource network of 780 employees focused on climate, health and equity. Melanie and Caitlyn work in different departments and came together through our IMPACT to help advance Biogen’s Healthy Climate, Healthy Lives goals.
They have run events such as Biogen beehive tours, native plant expositions, and group clean-ups of a vital water source in RTP, North Carolina. And, they are working on a closed-loop recycling program in RTP that could help cut costs while reducing waste.
Employee Innovation Challenge Inspires Change
In the past year, our employees have helped to address climate, health and equity. In 2021, Biogen hosted our first Healthy Climate, Healthy Lives Employee Innovation Challenge, which encouraged employees to share ideas that build towards our climate, health and equity goals. In total, we received 180+ ideas from 14 sites worldwide. As of 2022, four winners have received awards (pictured, Dan Blake, who won an award for his idea of him). All 180+ ideas underwent consideration, and many have already been implemented.
- Drive innovation, mitigate environmental and health impacts, and influence policy.
- Conducted the most comprehensive metaanalysis to date on air pollution and dementia with Harvard T. H. Chan School of Public Healthwhich was presented at the American Academy of Neurology in 2022.
- collaborated with the MIT Joint Program on the Science and Policy of Global Change and the Technology and Policy Program to develop a state-of-the-art integrated model of how various climate actions impact public health, including the Tool for Air Pollution Scenarios (TAPS). It is open source and available to the public.
- The World Business Council for Sustainable Development’s (WBCSD) Healthy People, Healthy Business project – a cross-sectoral coalition of 23 leading companies, co-chaired by Biogen – has been working to understand the connection between the environment and human health.
Helping community health clinics care for the most vulnerable amidst the climate crisis
Across the US, the climate crisis is threatening the ability of thousands of community health centers to care for millions of uninsured or underinsured patients. To address climate-related risks to their operations and patient health, biogene collaborated with Americares and the Harvard TH Chan School of Public Health (Harvard Chan C-CHANGE).
Together, we surveyed 450+ frontline clinic staff in 47 US states and territories, finding 81% of clinic staff experienced climate-related disruptions within the past three years. To respond, we introduced a new doctrine on patient-centered climate action, published in JAMA, to catalyze health sector and policy action and published first-ever resources to help. the Climate Resilient Health Clinics Toolkit has reached 2500 clinic providers and staff in a pioneering effort that is catalyzing support from others in the pharmaceutical sector.
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer’s disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, immunology, neurocognitive disorders, acute neurology and pain. We routinely post information that may be important to investors on our website at www.biogen.com. To learn more, please visit www.biogen.com and follow us on social media – Twitter, LinkedIn, Facebook, YouTube.
More from biogene